<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F71BABD-BB5E-465A-A468-AD99CA3C8DA6"><gtr:id>7F71BABD-BB5E-465A-A468-AD99CA3C8DA6</gtr:id><gtr:name>Bandim Health Project (BHP)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F71BABD-BB5E-465A-A468-AD99CA3C8DA6"><gtr:id>7F71BABD-BB5E-465A-A468-AD99CA3C8DA6</gtr:id><gtr:name>Bandim Health Project (BHP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2FEA791E-5E6C-4FD9-A97C-98EAEE9A1096"><gtr:id>2FEA791E-5E6C-4FD9-A97C-98EAEE9A1096</gtr:id><gtr:firstName>Hilton</gtr:firstName><gtr:surname>Whittle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190088487"><gtr:id>7B896633-372D-4F89-B3B5-3B68CA22ABB8</gtr:id><gtr:title>Two Dose E-Z Measles Vaccine Trial: Boosting of Immune Responses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190088487</gtr:grantReference><gtr:abstractText>Long term protection following vaccination is maintained by intermittent exposure to the organism that causes the disease. This results in a boost to the immune system without apparent disease. If coverage of a vaccine is high so that the organism ceases to circulate then it is necessary to boost the immune response with another dose of vaccine. Thus measles in African measles has been controlled by mass booster campaigns every 5 years. Surprisingly few detailed immunological studies have been conducted on the short and long term effects of this booster dose of measles or other vaccines. Thus we plan to measure substances in the blood that neutralizes the virus (antibodies) before and after another dose (booster dose) of measles vaccine is given. The children will have already received one or two doses of the vaccine previously. The concentration or level of these neutralizing antibodies two weeks after the boost will give us an idea if the two groups are equally likely to be protected from measles if naturally exposed. We will also measure antibody levels and protective substances that blood cells produce (cytokines) one year after the boost to see if protection persists.</gtr:abstractText><gtr:technicalSummary>Little is known of short term immune responses following a booster dose of measles vaccine in immunized children. We will compare the magnitude of these responses in three year old children who have received one or two doses of Edmonston-Zagreb measles vaccine in infancy during a previous trial in Sukuta (SCC 948). Two weeks after a booster dose of E-Z vaccine, gamma-interferon Elispot, lymphoproliferation and cytokine responses will be compared in the blood of the two groups of children. Long term antibody responses will be measured one year after the boost. We predict that cellular immune responses will be similar but antibody responses and persistence may differ.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>251287</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bandim Health Project (BHP)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>nonspecific effects of measles vaccines</gtr:description><gtr:id>7CD6FD05-527B-440D-9E28-F21BB7200836</gtr:id><gtr:impact>scientific papers produced as listed</gtr:impact><gtr:outcomeId>qJd3oUtJk9K-1</gtr:outcomeId><gtr:partnerContribution>field trials in guinea Bissau</gtr:partnerContribution><gtr:piContribution>advice on design of field trials, supervision of laboratory assays for measles antibody</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Symposium field workers- the Gambia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>14D594FF-4FCC-407B-B178-F3D9C795A84C</gtr:id><gtr:impact>Gave a powerpoint lecture to 30 people. No media impact.

increased knowledge of the project and discussed furthe rresearch plans</gtr:impact><gtr:outcomeId>7261D12B1DC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OPTIMISE (11.1m euros across 18 participants)</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>FFCC6C8B-2BF6-4988-8E3E-49DFCDE3F5CC</gtr:id><gtr:outcomeId>cMppzdwYSNW0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>non-specific effects of measles vaccines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>223059FB-0E45-4865-97B0-D897CA05493C</gtr:id><gtr:outcomeId>jQVmnPhKWPe</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CD152D9C-3E96-487F-BC62-6B52D5A1E5CB</gtr:id><gtr:title>Sex differences in the vaccine-specific and non-targeted effects of vaccines.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e16dca02a00616648b5fb16d77916ef0"><gtr:id>e16dca02a00616648b5fb16d77916ef0</gtr:id><gtr:otherNames>Flanagan KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>AY5HMJbVPHi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05324D1E-C586-46C2-ADF1-A12B54445311</gtr:id><gtr:title>Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dde3ec2e4243d5f05da5c43ba88f6efc"><gtr:id>dde3ec2e4243d5f05da5c43ba88f6efc</gtr:id><gtr:otherNames>Aaby P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>LRaMHjYASVt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEBB7833-1197-4F29-A629-84A73BAD810C</gtr:id><gtr:title>Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2525f95c10f90a7f12efaac3a819a869"><gtr:id>2525f95c10f90a7f12efaac3a819a869</gtr:id><gtr:otherNames>Njie-Jobe J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_14872_22_22314136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54F76D55-52B7-4047-81D0-E08CE92D8510</gtr:id><gtr:title>Risk factors for measles in young infants in an urban African area with high measles vaccination coverage.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd04886987690f86a4e23073db489914"><gtr:id>cd04886987690f86a4e23073db489914</gtr:id><gtr:otherNames>Bal? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>WfDaUgg1qpK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5006374E-F021-48DE-AE71-0EECE4DEE91F</gtr:id><gtr:title>The new decade of vaccines.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dde3ec2e4243d5f05da5c43ba88f6efc"><gtr:id>dde3ec2e4243d5f05da5c43ba88f6efc</gtr:id><gtr:otherNames>Aaby P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_14872_22_22225660</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190088487</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>